|Bid||1.2800 x 2200|
|Ask||1.3900 x 4000|
|Day's Range||1.3200 - 1.3600|
|52 Week Range||0.3820 - 3.5780|
|Beta (3Y Monthly)||5.51|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On a per-share basis, the Chesterbrook, Pennsylvania-based company said it had a loss of 6 cents. The company's shares closed at $1.55. A year ago, they were trading at $1.98. _____ This story was generated ...
During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.
Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.
Trevena, Inc. (NASDAQ:TRVN) shareholders will doubtless be very grateful to see the share price up 164% in the last quarter. But that is meagre solace in the face of the shocking decline over three years. Indeed, the share...
Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.
The company could not say exactly when it will resubmit is new drug application for oliceridine, which was rejected by the FDA late last year.
PDL BioPharma's (PDLI) earnings exceed estimates in Q4. Lower royalties as well as weak product sales induce a downfall in year-over-year revenues.
Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.
On a per-share basis, the Chesterbrook, Pennsylvania-based company said it had a loss of 10 cents. The biopharmaceutical company posted revenue of $232,000 in the period. For the year, the company reported ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who reallyRead More...
The Chester County biopharmaceutical expects to initiate a new study for its experimental pain medicine, requested by the FDA, during the first half of this year.
Trevena Stock Soars on Positive Response from FDAStock price jumpOn January 28, Trevena (TRVN) closed at $1.19, which is 119.96% higher than its previous closing price. This spike was in response to the company’s press release that announced the
One week after the Food and Drug Administration turned down the company's application for its lead new drug candidate, Trevena Inc. said it's reducing its workforce by about a third as part of a corporate restructuring. Trevena (NSADQ: TRVN) officials said the company is undertaking additional cost-saving initiatives that, in total, are expected to save it more than $3.5 million a year. "Following receipt of the Complete Response Letter for oliceridine, we must act to reduce operating costs and conserve our capital resources,” said Carrie L. Bourdow, Trevena's president and CEO, in a statement.
The Chesterbrook, Pennsylvania-based company said it had a loss of 6 cents per share. The biopharmaceutical company posted revenue of $3 million in the period. The company's shares closed at 61 cents. ...
Trevena says it plans to continue to work with the FDA to address the issues that caused the agency to reject the company's new drug application for Olinvo.
Trevena Inc said on Friday the U.S. Food and Drug Administration declined to approve its opioid injection for managing acute pain. The FDA in its complete response letter requested additional clinical data and indicated that the safety data was not adequate for the proposed dosing. Opioid addiction and overdose have become a serious public health crisis in the United States.